New York, June 5, 2026, 19:02 (EDT)
BGM Group Ltd. shares closed down 10.49% at $0.2910 on Friday, taking the Nasdaq stock closer to its 52-week lows. Just 164,340 shares traded hands, well under the recent average of 236,148, according to market data.
BGM is still weighed down by a June financing. In a May SEC filing, the company said it struck a deal to sell 200 million Class A ordinary shares for 6 cents apiece, plus it will issue warrants giving holders an option to buy as many as 200 million more shares later.
BGM is raising cash through a private placement, selling securities to a group of chosen investors and not the public. The company said it plans to use the money for working capital and general corporate needs. BGM expects to close the deal in June, depending on certain conditions. After the close, there will be 380.6 million Class A shares outstanding, according to a filing.
The 6-cent discount on the financing stands out against Friday’s 29.1-cent close. It doesn’t predict where the stock goes from here, but immediately puts the focus on dilution—current holders get squeezed when a company sells lots of new shares.
Stocks tanked after U.S. jobs numbers came in hot, with the Nasdaq Composite down 4.18%. The S&P 500 dropped 2.64% and the Dow fell 1.35%. “The dam just broke today,” Carson Group chief market strategist Ryan Detrick told Reuters. Wells Fargo’s Ohsung Kwon called it “more driven by positioning rather than fundamentals.” Reuters
BGM faces pressure from more than just Friday’s market session. Back in April, the company said Nasdaq hit it with a deficiency notice because its closing bid price sat under $1.00 for 30 straight business days. The company now has a deadline of Oct. 21, 2026, to get its closing bid back up to at least $1.00 for 10 business days in a row to regain compliance.
BGM shares weren’t hit by the notice right away, but the clock is ticking. The company said it’s looking at options, like a reverse stock split to push up the share price by cutting down the share count. BGM added there’s no guarantee it will fall back in line with the rules.
BGM says it operates across artificial intelligence, robots, computing power, cloud computing and biopharma. Its AI insurance services, Du Xiao Bao and Bao Wang, target insurers, brokers and consumers. On the drug side, BGM produces oxytetracycline APIs, crude heparin sodium and licorice products.
AI has been at the center of the company’s recent moves. In December, AIX Inc. agreed to transfer its intelligent insurance platform and RONS Intelligent Technology to BGM. The deal: about 70 million BGM Class A shares. BGM CEO Xin Chen said the plan is to use AI for insurance and healthcare. AIX CEO Yinan Hu called the move an effort to “lead the transformation” in those areas. GlobeNewswire
MarketBeat’s screens group BGM with pharma product players like PepGen, LENZ Therapeutics, and Bicycle Therapeutics, but it’s not a clean read. BGM does drug manufacturing, but it also has AI insurance assets and faces unique listing pressure, so the match doesn’t line up well.
The risk can go either direction. Getting the placement done would add cash and could buy management some time if it steadies operations and reporting. But more shares, thin micro-cap demand, or another setback on compliance mean holders could still get hit on the downside—like a reverse split, more funding rounds, or delisting if they miss the $1 mark.
BGM is also under filing pressure. The company said in February it got another Nasdaq notice, this one because of a late Form 20-F annual report. That notice did not have an immediate impact on the listing, as BGM worked on a plan to comply.
BGM traders head into next week looking for a filing. The main question isn’t a big strategy shift, just whether the placement finished, got altered, or hit a snag. For now, the market sees BGM as a sub-30-cent name still playing for time.
